

Shahid A Khan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8396247/publications.pdf>

Version: 2024-02-01

37
papers

7,428
citations

394286

19
h-index

345118

36
g-index

39
all docs

39
docs citations

39
times ranked

7518
citing authors

#	ARTICLE	IF	CITATIONS
1	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 557-588.	8.2	1,155
2	Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2014, 60, 1268-1289.	1.8	1,151
3	Cholangiocarcinoma – evolving concepts and therapeutic strategies. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 95-111.	12.5	1,051
4	Cholangiocarcinoma. <i>Lancet</i> , The, 2005, 366, 1303-1314.	6.3	1,029
5	Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. <i>Gut</i> , 2012, 61, 1657-1669.	6.1	678
6	Changing international trends in mortality rates for liver, biliary and pancreatic tumours. <i>Journal of Hepatology</i> , 2002, 37, 806-813.	1.8	508
7	Cholangiocarcinoma: Epidemiology and risk factors. <i>Liver International</i> , 2019, 39, 19-31.	1.9	420
8	Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2020, 72, 95-103.	1.8	286
9	Cholangiocarcinoma. <i>Nature Reviews Disease Primers</i> , 2021, 7, 65.	18.1	270
10	Rising trends in cholangiocarcinoma: Is the ICD classification system misleading us?. <i>Journal of Hepatology</i> , 2012, 56, 848-854.	1.8	260
11	A Comprehensive Analysis of Common Genetic Variation Around Six Candidate Loci for Intrahepatic Cholestasis of Pregnancy. <i>American Journal of Gastroenterology</i> , 2014, 109, 76-84.	0.2	103
12	Multivalent Nanoparticle Networks Enable Point-of-Care Detection of Human Phospholipase-A2 in Serum. <i>ACS Nano</i> , 2015, 9, 2565-2573.	7.3	97
13	p53 mutations in human cholangiocarcinoma: a review. <i>Liver International</i> , 2005, 25, 704-716.	1.9	64
14	Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2019, 116, 56-66.	1.3	48
15	Proton and phosphorus-31 nuclear magnetic resonance spectroscopy of human bile in hepatopancreaticobiliary cancer. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 733-738.	0.8	43
16	In vivo and in vitro nuclear magnetic resonance spectroscopy as a tool for investigating hepatobiliary disease: a review of ¹ H and ³¹ P MRS applications. <i>Liver International</i> , 2005, 25, 273-281.	1.9	36
17	Incidence and mortality of primary liver cancer in England and Wales: Changing patterns and ethnic variations. <i>World Journal of Gastroenterology</i> , 2014, 20, 1544.	1.4	33
18	Ablative Therapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis. <i>Journal of Clinical and Experimental Hepatology</i> , 2019, 9, 740-748.	0.4	25

#	ARTICLE	IF	CITATIONS
19	Viral hepatitis prevalence in patients with active and latent tuberculosis. <i>World Journal of Gastroenterology</i> , 2015, 21, 8920.	1.4	20
20	Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2019, 71, 1261-1262.	1.8	17
21	Cholangiocarcinoma miscoding in hepatobiliary centres. <i>European Journal of Surgical Oncology</i> , 2021, 47, 635-639.	0.5	17
22	Epidemiology of HPB malignancy in the elderly. <i>European Journal of Surgical Oncology</i> , 2021, 47, 503-513.	0.5	15
23	The clinical role of circulating free tumor DNA in gastrointestinal malignancy. <i>Translational Research</i> , 2017, 183, 137-154.	2.2	14
24	The risk factors and diagnosis of cholangiocarcinoma. <i>Hepatology International</i> , 2013, 7, 377-393.	1.9	13
25	Androgenic anabolic steroid-induced liver injury: two case reports assessed for causality by the updated Roussel Uclaf Causality Assessment Method (RUCAM) score and a comprehensive review of the literature. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000549.	1.1	12
26	Plasma Lipid Profiling in a Rat Model of Hepatocellular Carcinoma: Potential Modulation Through Quinolone Administration. <i>Journal of Clinical and Experimental Hepatology</i> , 2015, 5, 286-294.	0.4	10
27	Polymorphisms in Natural Killer Cell Receptor Protein 2D (NKG2D) as a Risk Factor for Cholangiocarcinoma. <i>Journal of Clinical and Experimental Hepatology</i> , 2019, 9, 171-175.	0.4	9
28	Phospholipase A2 as a point of care alternative to serum amylase and pancreatic lipase. <i>Nanoscale</i> , 2016, 8, 11834-11839.	2.8	8
29	Exploring Metabolic Consequences of CPS1 and CAD Dysregulation in Hepatocellular Carcinoma by Network Reconstruction. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 1-9.	1.8	8
30	Analysis of p53 mutations for a mutational signature in human intrahepatic cholangiocarcinoma. <i>International Journal of Oncology</i> , 2006, 28, 1269-77.	1.4	8
31	The role of miRNAs in cholangiocarcinoma. <i>Hepatic Oncology</i> , 2016, 3, 167-180.	4.2	5
32	Nation-wide trends in non-alcoholic steatohepatitis (NASH) in patients with and without diabetes between 2004 and 2014-15 in England. <i>Diabetes Research and Clinical Practice</i> , 2017, 132, 102-107.	1.1	4
33	Reply to: "Letter regarding [Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis]"™. <i>Journal of Hepatology</i> , 2020, 72, 1217.	1.8	4
34	BMAT's predictive validity for medical school performance: A retrospective cohort study. <i>Medical Education</i> , 2022, 56, 936-948.	1.1	4
35	Photodynamic therapy significantly improves survival outcomes in people with non-resectable cholangiocarcinoma. <i>Cancer Treatment Reviews</i> , 2004, 30, 315-318.	3.4	2
36	Mutations in circulating cell-free tumour DNA: Predictors of survival in hepatocellular carcinoma. <i>Liver Cancer International</i> , 2021, 2, 54-62.	0.2	1

#	ARTICLE	IF	CITATIONS
37	Interview: Challenges and prospects for liver cancer management: treatment, prevention and collaboration. Hepatic Oncology, 2014, 1, 17-21.	4.2	0